Randomised clinical trial: Vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

B.G. Feagan, W.J. Sandborn, G. D'Haens, S.D. Lee, M. Allez, R.N. Fedorak, U. Seidler, S. Vermeire, Ian Lawrance, A.C. Maroney, C.H. Jurgensen, A. Heath, D.J. Chang

    Research output: Contribution to journalArticlepeer-review

    52 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Randomised clinical trial: Vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease'. Together they form a unique fingerprint.

    Medicine & Life Sciences